Big Pharma-backed Sitryx locks an additional $39M in a Series A raise to advance its immunometabolic pipeline
Sitryx Therapeutics has raised an additional £32 million ($39 million) in a follow-on to its 2018 Series A to help push its immunometabolic pipeline into the clinic.
New investor Oxford Science Enterprises (OSE) joins the fray with Big Pharma backers GSK and Eli Lilly, as well as Sofinnova Partners, SV Health Investors and Longwood Fund. The Oxford, UK-based company made its debut in 2018 with a $30 million Series A, bringing its total fundraising to more than $75 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.